Overview

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Status:
RECRUITING

Trial end date:
2029-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

Phase:

PHASE1

Details

Lead Sponsor:

Alterome Therapeutics, Inc.